Vera Therapeutics, Inc. Contracts & Agreements
44 Contracts & Agreements
- Business Finance (15 contracts)
- Business Operations (1)
- Human Resources (11)
- Intellectual Property (4)
- Uncategorized (13)
- Vera Therapeutics, Inc. 2024 Inducement Plan, as amended (Filed With SEC on November 7, 2024)
- Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., dated October 29, 2024 (Filed With SEC on October 31, 2024)
- Offer Letter, by and between the Registrant and David Johnson, dated June 26, 2024 (Filed With SEC on August 8, 2024)
- Offer Letter, by and between the Company and David Johnson, dated June 26, 2024 (Filed With SEC on July 2, 2024)
- Offer Letter, by and between the Registrant and Robert Brenner, M.D., dated January 3, 2024 (Filed With SEC on May 10, 2024)
- Offer Letter, by and between the Registrant and William Turner, dated December 19, 2023 (Filed With SEC on May 10, 2024)
- Description of Common Stock of the Registrant (Filed With SEC on March 27, 2024)
- Vera Therapeutics, Inc. 2024 Inducement Plan (Filed With SEC on March 27, 2024)
- Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2024 Inducement Plan (Filed With SEC on March 27, 2024)
- Form of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc. 2024 Inducement Plan (Filed With SEC on March 27, 2024)
- Vera Therapeutics, Inc. Non-employee Director Compensation Policy, as amended December 6, 2023 (Filed With SEC on March 27, 2024)
- Separation Agreement by and between the Registrant and Celia Lin, M.D., dated January 3, 2024 (Filed With SEC on March 27, 2024)
- Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., dated January 29, 2024 (Filed With SEC on January 30, 2024)
- Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., dated February 1, 2023 (Filed With SEC on February 2, 2023)
- First Amendment to Loan and Security Agreement, by and between the Registrant and Oxford Finance, LLC, dated November 4, 2022 (Filed With SEC on November 9, 2022)
- Amendment to License Agreement, dated September 9, 2022, by and between the Company and Novartis Pharma AG (Filed With SEC on September 9, 2022)
- Description of Common Stock of the Registrant (Filed With SEC on March 28, 2022)
- Form of Underwriting Agreement (Filed With SEC on February 7, 2022)
- Loan and Security Agreement between the Registrant and Oxford Finance LLC, dated December 17, 2021 (Filed With SEC on February 7, 2022)
- Asset Purchase Agreement between the Registrant and Amplyx Pharmaceuticals, Inc. dated December 16, 2021 (Filed With SEC on February 7, 2022)
- License Agreement between Novartis International Pharmaceutical AG and Amplyx Pharmaceuticals, Inc. dated August 26, 2019 (Filed With SEC on February 7, 2022)
- Amendment No. 1 to License Agreement between Novartis International Pharmaceutical AG and Amplyx Pharmaceuticals, Inc. dated September 24, 2019 (Filed With SEC on February 7, 2022)
- Offer Letter, by and between the Company and Sean P. Grant, dated May 30, 2021 (Filed With SEC on July 14, 2021)
- Form of Underwriting Agreement (Filed With SEC on May 10, 2021)
- Form of Class A Common Stock Certificate (Filed With SEC on May 10, 2021)
- Vera Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on May 10, 2021)
- Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on May 10, 2021)
- Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on May 10, 2021)
- Vera Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on May 10, 2021)
- Vera Therapeutics, Inc. 2021 Non-Employee Director Compensation Policy (Filed With SEC on May 10, 2021)
- Form of Indemnification Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on May 10, 2021)
- Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated May 7, 2021 (Filed With SEC on May 10, 2021)
- Amended and Restated Offer Letter by and between the Registrant and Joanne Curley, Ph.D., dated May 7, 2021 (Filed With SEC on May 10, 2021)
- Amended and Restated Offer Letter by and between the Registrant and Celia Lin, M.D., dated May 7, 2021 (Filed With SEC on May 10, 2021)
- Second Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated October 29, 2020 (Filed With SEC on April 23, 2021)
- Vera Therapeutics, Inc. 2017 Equity Incentive Plan (Filed With SEC on April 23, 2021)
- Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2017 Equity Incentive Plan (Filed With SEC on April 23, 2021)
- Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated December 22, 2020 (Filed With SEC on April 23, 2021)
- Offer Letter by and between the Registrant and Joanne Curley, Ph.D., dated February 5, 2020 (Filed With SEC on April 23, 2021)
- Amendment to Employment Agreement by and between the Registrant and Joanne Curley, Ph.D., dated September 3, 2020 (Filed With SEC on April 23, 2021)
- Confidential Consulting Agreement by and between the Registrant and FLG Partners, LLC, dated March 15, 2020 (Filed With SEC on April 23, 2021)
- Offer Letter by and between the Registrant and Allen Ebens, Ph.D., dated July 26, 2018 (Filed With SEC on April 23, 2021)
- Separation Agreement by and between the Registrant and Allen Ebens, Ph.D., dated September 24, 2020 (Filed With SEC on April 23, 2021)
- License Agreement by and between the Registrant and Ares Trading S.A., dated as of October 29, 2020 (Filed With SEC on April 23, 2021)
